(Q37590046)

21 August 2017

1 reference

title

Platelet function testing and implications for clinical practice (English)

1 reference

21 August 2017

2

Gilles Montalescot

1 reference

21 August 2017

1

Jean-Philippe Collet

1 reference

21 August 2017

publication date

1 September 2009

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

157-169

1 reference

Thrombin and platelet activation

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Activation of platelet function through G protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Cell adhesion mechanisms in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Platelet function testing in cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Platelets in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Mechanisms of thrombus formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Aspirin resistance: position paper of the Working Group on Aspirin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Aspirin dose for the prevention of cardiovascular disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Drug interactions with tobacco smoking. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibati

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248409339309

21 January 2018

Identifiers

DOI

10.1177/1074248409339309

1 reference

21 August 2017

1 reference